Back to search results

Impact of Dysbiosis-inducing Drugs on Effectivity of Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer Patients

Abroad (travel likely)Recruiting

Conditions

Dysbiosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Service de Pneumologie - CHU de Strasbourg - France, Strasbourg, France

    Contact: Study coordinator (Céline MASCAUX, MD, PhD) · celine.mascaux@chru-strasbourg.fr · 33.3.69.55.06.39
    Contact: Principal Investigator (Céline MASCAUX, MD, PhD)
    Sébastien Lopes, MD (Sub-investigator)
    Lucile Pabst, MD (Sub-investigator)
    Quentin Creusot, MD (Sub-investigator)
    Bertrand Basil, PhD (Sub-investigator)
    Thibaut Goetsch, MD (Sub-investigator)
    Sarah Fischer, Psychologist (Sub-investigator)
    Guillaume Pamart, MD (Sub-investigator)
    Cézar Matau, MD (Sub-investigator)
    Koukeb Rougieg, CRA (Sub-investigator)
    Justine Dumont, MD (Sub-investigator)
    Gourieux Gourieux, PharmD (Sub-investigator)
    Erwan Pencreach, PharmD (Sub-investigator)
    Michele Beau-Faller, MD, PhD (Sub-investigator)
    Anne Dory, MD (Sub-investigator)
View source on ClinicalTrials.gov(opens in a new tab)Contact study team (email)